Effect of polymorphism in CYP2C19 on Pharmacokinetics of Omeprazole in Indigenous Population

Omeprazole, a proton pump inhibitor (PPI) is one of the most widely prescribed drugs used world wide and is available over-the-counter in some countries. According to the results of numerous clinical studies, CYP2C19 polymorphisms is an important factor affecting the pharmacokinetics of most PPIs.According to some research,Asian populations is characterized by high prevalence of defect CYP2C19alleles.But there is no data available about genotyping of our population. That shows the importance of pharmacogenomics before pharmacokinetic and bioequvalence studies in our population.In this study the pharmacokinetic parameters of omeprazole in 200 human volunteers (100 male and 100 female) are evaluated and the genetic polymorphism of allele CYP2C19 by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) are identified.So that by finding and identifying genotypes of every participant it is evaluated that whether the volunteers are extensive, intermediate or poor metabolisers and variation among their pharmacokinetic parameters are compared. In Pakistan where people belong from different cultures and races, evaluation of genetic polymorphism is essentail for minimizing the adverse effects and calculating the accurate dose of drug. KeywordsOmeprazole, genotyping, pharmacokinetics, genetic